OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2

Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic …

Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from ...
Nasdaq

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Clinical data from Phase 1b prostate cancer trial to be released in Q4/25 Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the ...
Seeking Alpha

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully ...

75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
Precision Medicine Online

OS Therapies to Seek Approval for OST-HER2 Cancer Vaccine in Osteosarcoma in US, UK, Europe

The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.
Seeking Alpha

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...